Alpha Cognition Reports Strong ZUNVEYL Revenue Growth and 2-Year Cash Runway in FY2025 Results
ACOG sits 38% above its 52-week low of $3.75.
Summary
Alpha Cognition Inc. announced its full-year 2025 financial results, highlighting significant growth in ZUNVEYL product revenue, expansion of PBM contracts, and a robust cash position providing a two-year runway.
Key Events · Earnings and Guidance · ACOG
-
Strong ZUNVEYL Revenue Growth
Full-year 2025 total revenue reached $10.2 million, driven by $6.8 million in ZUNVEYL net product revenue, with Q4 sales up 62% quarter-over-quarter.
-
Expanded PBM Coverage
Secured a second national PBM contract, enhancing market access for ZUNVEYL in long-term care.
-
Solid Cash Position
Ended 2025 with $66 million in cash and cash equivalents, providing an estimated two-year operating runway.
-
Increased Operating Expenses
Selling, General & Administrative expenses rose to $29.1 million, reflecting significant investment in commercial infrastructure.
Analysis · ACOG · Life Sciences
This 8-K provides detailed financial and operational results for fiscal year 2025, confirming the company's commercial progress with ZUNVEYL. Despite reporting a net loss, the substantial increase in product revenue, successful expansion of PBM coverage, and a strong cash balance of $66 million (providing an estimated two-year runway) are critical positives. These factors indicate successful execution of its commercial strategy and reduced near-term financing risk, which is vital for a biopharmaceutical company. Investors should monitor continued ZUNVEYL adoption and progress towards operational profitability in 2027.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 30% of the 1759 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACOG was trading at $5.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $116.1M. The 52-week trading range was $3.75 to $11.54. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.